In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Autolus Therapeutics Plc (AUTL), with a price target of $45. The company’s shares closed on Friday at $39.02.
“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.61, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.8% and a 36.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Autolus Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $47.50, implying a 21.7% upside from current levels. In a report issued on November 28, Wells Fargo also maintained a Buy rating on the stock with a $50 price target.
The company has a one-year high of $53.24 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 56.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The company portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. Autolus Therapeutics was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.